The company will feature the Endeavor Zotarolimus-Eluting Coronary Stent System, which was approved by the FDA in February 2008. Data from more than 4,100 patients followed up for as long as four years showed the stent provided a consistent and sustained reduction in the need for repeat procedures compared to a bare-metal stent.
It will also feature the Reveal DX Insertable Cardiac Monitor, a device that is placed just under the skin of the chest to record data before, during and after a syncopal event. It is not yet available in the U.S., but has received CE Mark.
Another highlighted product is the Cardioblate Gemini, an endoscopic ablation device for stand-alone procedures.